AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Cynata has opened recruitment in its Phase 2 clinical trial of CYP-001 in high-risk aGvHD.
- Under the global trial, around 60 patients are targeted to be recruited.
- The company expects to conclude recruitment for the trial by the end of 2024 and primary results in 2H25.
Cynata Therapeutics Limited (ASX: CYP) has opened the patient recruitment for Phase 2 clinical study of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD).
Cynata highlighted that the global trial would aim to enrol nearly 60 patients with HR-aGvHD. The recruited patients will be randomised to receive either steroids plus placebo or steroids plus CYP-001.
The first clinical centre to open for recruitment is Westmead Hospital, Sydney, Australia. The trial will be led by Professor David Gottlieb, who is a professor of Haematology at The University of Sydney. He is also the director of the blood transplant & cell therapies program at Westmead Hospital.
Cynata, a clinical-stage biotechnology company specialising in cell therapeutics, is managing and funding the trial.
Data source: Company update
The company expects the completion of enrolment by the end of 2024 and release the primary evaluation results in the second half of 2025.
CYP shares traded at AU$0.145 at the time of writing on 10 August 2023.